BIAF
bioAffinity Technologies Inc
$
0.294
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.3161
Open
0.305
VWAP
0.30
Vol
593.48K
Mkt Cap
8.26M
Low
0.280
Amount
177.61K
EV/EBITDA(TTM)
--
Total Shares
11.36M
EV
9.47M
EV/OCF(TTM)
--
P/S(TTM)
0.49
bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2024Q1
--
--
-0.100
-47.37%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for bioAffinity Technologies, Inc. (BIAF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -38.19%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-38.19%
In Past 3 Month
1 Analyst Rating
1943.60% Upside
Wall Street analysts forecast BIAF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIAF is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
1943.60% Upside
Current: 0.294
Low
6.00
Averages
6.00
High
6.00
1943.60% Upside
Current: 0.294
Low
6.00
Averages
6.00
High
6.00
Maxim Group
Anthony Vendetti
Strong Buy
to
Hold
Downgrades
n/a
2025-04-01
Reason
Maxim Group
Anthony Vendetti
Price Target
n/a
2025-04-01
Downgrades
Strong Buy
to
Hold
Reason
Maxim downgraded BioAffinity Technologies to Hold from Buy.
See All Ratings
Valuation Metrics
The current forward P/E ratio for bioAffinity Technologies Inc (BIAF.O) is -0.95, compared to its 5-year average forward P/E of -2.16. For a more detailed relative valuation and DCF analysis to assess bioAffinity Technologies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.16
Current PE
-0.95
Overvalued PE
-1.26
Undervalued PE
-3.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.95
Current PS
1.30
Overvalued PS
1.96
Undervalued PS
-0.06
Financials
Annual
Quarterly
FY2025Q1
YoY :
-22.97%
1.85M
Total Revenue
FY2025Q1
YoY :
+35.06%
-2.63M
Operating Profit
FY2025Q1
YoY :
+35.61%
-2.66M
Net Income after Tax
FY2025Q1
YoY :
-20.00%
-0.16
EPS - Diluted
FY2025Q1
YoY :
-29.10%
-1.69M
Free Cash Flow
FY2025Q1
YoY :
-37.08%
17.87
Gross Profit Margin - %
FY2025Q1
YoY :
-45.88%
-75.48
FCF Margin - %
FY2025Q1
YoY :
+76.05%
-143.53
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
1
876.4K
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BIAF News & Events
Events Timeline
2025-07-22 (ET)
2025-07-22
09:21:45
BioAffinity Technologies awarded new Canadian patent for CyPath Lung
2025-07-15 (ET)
2025-07-15
09:03:55
BioAffinity receives China patent for noninvasive lung cancer diagnostic
2025-06-24 (ET)
2025-06-24
09:13:29
BioAffinity Technologies gets China patent for siRNA-based cancer therapy
Sign Up For More Events
Sign Up For More Events
News
6.5
06-30NASDAQ.COMTop Research Reports for Meta Platforms, ServiceNow & Booking
9.0
06-26NASDAQ.COMVOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
9.0
06-26NewsfilterbioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
Sign Up For More News
People Also Watch
XELB
Xcel Brands Inc
1.100
USD
-19.12%
TSBX
Turnstone Biologics Corp
0.350
USD
-0.85%
MHUA
Meihua International Medical Technologies Co Ltd
0.369
USD
-2.64%
SQFT
Presidio Property Trust Inc
5.800
USD
+3.39%
SGMA
SigmaTron International Inc
3.010
USD
-0.33%
ICU
SeaStar Medical Holding Corp
0.655
USD
+7.56%
HOTH
Hoth Therapeutics Inc
1.305
USD
-1.88%
RVYL
Ryvyl Inc
0.263
USD
0.00%
GVH
Globavend Holdings Ltd
5.140
USD
-8.87%
FAQ
What is bioAffinity Technologies Inc (BIAF) stock price today?
The current price of BIAF is 0.2936 USD — it has decreased -7.26 % in the last trading day.
What is bioAffinity Technologies Inc (BIAF)'s business?
What is the price predicton of BIAF Stock?
What is bioAffinity Technologies Inc (BIAF)'s revenue for the last quarter?
What is bioAffinity Technologies Inc (BIAF)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for bioAffinity Technologies Inc (BIAF)'s fundamentals?
How many employees does bioAffinity Technologies Inc (BIAF). have?